Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $27. The company’s shares opened today at $5.25.
Tanner said:
“: We reiterate the Overweight rating and raise our PT for TXMD stock by $1 to $27. After many years of underperformance (essentially unchanged since Dec. 31 2013 [albeit with +~83% dilution] vs. +55% for the NBI), despite corporate progress that includes FDA approval of Imvexxy and positive pivotal data for TX-001, we believe the next 12-18 months could be a period of positive stock performance if the company executes on the commercial front.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 2.0% and a 44.0% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Supernus Pharmaceuticals, and Aquinox Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $17.50 average price target, representing a 233.3% upside. In a report issued on July 30, Oppenheimer also reiterated a Buy rating on the stock with a $12 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.66 and a one-year low of $4.34. Currently, TherapeuticsMD has an average volume of 3.19M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
